Zetagen Therapeutics Inc. products

ZetaDent is an osteo-inductive biologic intended to promote bone formation as a part of localized ridge augmentation procedures prior to dental implant placement, alveolar ridge reconstruction procedures for prosthetic treatment, and for filling of bone defects in the oral cavity.

ZetaFuse is the first synthetic, small molecule, osteo-inductive biologic, to safely aid bone healing of spinal fusions. The U.S. Food and Drug Administration (FDA) has awarded ZetaFuse Breakthrough Device Designation[1] for the complete spinal column. ZetaFuse is driven by the activation of a novel molecular pathway, by leveraging this patented mechanism, to directly turn stem cells into osteoblasts (osteoinductive) and prevents bone resorption (anti-osteolytic).

ZetaBase is an osteo-conductive and osteo-promotive therapy and is intended for the use as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. ZetaBase Bone Graft can be used as a bone graft extender.

ZetaSet is the first synthetic, osteo-inductive, biologic designed specifically for the treatment of osteoporotic fractures, high energy injuries with bone defects, and for patients with fractures of the tibial plateau (knee) and plafond (ankle).

ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.